Aldeyra Therapeutics (ALDX) Competitors $6.06 +0.95 (+18.59%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$6.06 +0.00 (+0.07%) As of 03/3/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALDX vs. ARQT, GERN, KNSA, DYN, LQDA, SNDX, NRIX, PRAX, DAWN, and ARDXShould you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Arcutis Biotherapeutics (ARQT), Geron (GERN), Kiniksa Pharmaceuticals (KNSA), Dyne Therapeutics (DYN), Liquidia (LQDA), Syndax Pharmaceuticals (SNDX), Nurix Therapeutics (NRIX), Praxis Precision Medicines (PRAX), Day One Biopharmaceuticals (DAWN), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical preparations" industry. Aldeyra Therapeutics vs. Arcutis Biotherapeutics Geron Kiniksa Pharmaceuticals Dyne Therapeutics Liquidia Syndax Pharmaceuticals Nurix Therapeutics Praxis Precision Medicines Day One Biopharmaceuticals Ardelyx Aldeyra Therapeutics (NASDAQ:ALDX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking. Which has more volatility & risk, ALDX or ARQT? Aldeyra Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Do insiders & institutionals believe in ALDX or ARQT? 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 8.5% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts prefer ALDX or ARQT? Aldeyra Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 65.02%. Arcutis Biotherapeutics has a consensus price target of $18.00, indicating a potential upside of 40.30%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aldeyra Therapeutics is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is ALDX or ARQT more profitable? Aldeyra Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Aldeyra Therapeutics' return on equity of -43.01% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aldeyra TherapeuticsN/A -43.01% -33.62% Arcutis Biotherapeutics -140.97%-119.11%-45.95% Does the media refer more to ALDX or ARQT? In the previous week, Arcutis Biotherapeutics had 28 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 34 mentions for Arcutis Biotherapeutics and 6 mentions for Aldeyra Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.50 beat Aldeyra Therapeutics' score of -0.09 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 7 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Which has higher valuation & earnings, ALDX or ARQT? Aldeyra Therapeutics has higher earnings, but lower revenue than Arcutis Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAldeyra TherapeuticsN/AN/A-$37.54MN/AN/AArcutis Biotherapeutics$196.54M7.74-$262.14M-$1.16-11.06 Does the MarketBeat Community believe in ALDX or ARQT? Aldeyra Therapeutics received 416 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 69.40% of users gave Aldeyra Therapeutics an outperform vote while only 66.34% of users gave Arcutis Biotherapeutics an outperform vote. CompanyUnderperformOutperformAldeyra TherapeuticsOutperform Votes48369.40% Underperform Votes21330.60% Arcutis BiotherapeuticsOutperform Votes6766.34% Underperform Votes3433.66% SummaryAldeyra Therapeutics beats Arcutis Biotherapeutics on 10 of the 15 factors compared between the two stocks. Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALDX vs. The Competition Export to ExcelMetricAldeyra TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$360.87M$7.22B$5.82B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E RatioN/A6.2025.0519.21Price / SalesN/A188.02375.96110.22Price / CashN/A65.6738.0534.58Price / Book2.976.447.334.28Net Income-$37.54M$139.24M$3.19B$247.04M7 Day Performance-6.77%-5.47%-4.36%-4.36%1 Month Performance17.21%-8.51%-6.01%-5.59%1 Year Performance43.60%-14.56%11.57%3.39% Aldeyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALDXAldeyra Therapeutics1.6543 of 5 stars$6.06+18.6%$10.00+65.0%+43.6%$360.87MN/A0.0015Earnings ReportAnalyst ForecastGap UpHigh Trading VolumeARQTArcutis Biotherapeutics3.3937 of 5 stars$12.39-4.8%$16.60+34.0%+9.0%$1.45B$59.61M-6.92150Earnings ReportAnalyst RevisionGERNGeron4.4791 of 5 stars$2.39-7.0%$6.91+189.1%-24.3%$1.44B$29.48M-7.4770Earnings ReportAnalyst RevisionNews CoverageKNSAKiniksa Pharmaceuticals2.4049 of 5 stars$19.63-1.9%$36.60+86.4%-1.3%$1.42B$270.26M-140.20220Earnings ReportShort Interest ↑DYNDyne Therapeutics3.192 of 5 stars$13.59-3.0%$49.91+267.2%-57.7%$1.38BN/A-3.82100Earnings ReportAnalyst ForecastAnalyst RevisionLQDALiquidia2.9688 of 5 stars$15.89-1.4%$25.38+59.7%+2.4%$1.34B$15.61M-9.7550News CoverageSNDXSyndax Pharmaceuticals3.6184 of 5 stars$15.67-4.3%$36.20+131.0%-34.7%$1.34B$16M-4.32110Earnings ReportNews CoverageGap UpNRIXNurix Therapeutics2.0094 of 5 stars$16.86-0.1%$31.81+88.7%+4.6%$1.28B$54.55M-5.83300News CoveragePositive NewsPRAXPraxis Precision Medicines2.309 of 5 stars$66.71-10.4%$145.20+117.7%-32.3%$1.24B$2.45M-6.48110Earnings ReportAnalyst ForecastNews CoverageDAWNDay One Biopharmaceuticals2.5667 of 5 stars$12.18-2.0%$35.71+193.2%-52.7%$1.23BN/A-11.8360Earnings ReportAnalyst RevisionARDXArdelyx4.5864 of 5 stars$5.13+1.4%$9.93+93.5%-45.6%$1.22B$251.85M-32.0690 Related Companies and Tools Related Companies ARQT Competitors GERN Competitors KNSA Competitors DYN Competitors LQDA Competitors SNDX Competitors NRIX Competitors PRAX Competitors DAWN Competitors ARDX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALDX) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALDX Stock Alerts